Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 11/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | PPARA | Q07869 | 5/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | MAPK7 | Q13164 | 2/20 | 0.37 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.36 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6424855 | 0.98 | PPARG (0.39) | PPARGHRH3PPARAHSD11B1EPHX2 | |
| SCHEMBL6423643 | 0.91 | MGLL (0.39) | PPARGHRH3PPARAMAPK7MGLL | |
| SCHEMBL6427114 | 0.90 | PPARG (0.42) | PPARGPPARAMAPK7AKR1C3AKR1C2 | |
| SCHEMBL5559188 | 0.89 | PTGS2 (0.39) | PPARGHRH3PPARAMAPK7MGLL | |
| SCHEMBL6422766 | 0.89 | MEN1 (0.35) | PPARGPPARAAKR1C3AKR1C2 | |
| SCHEMBL6426816 | 0.89 | SRC (0.42) | HSD11B1AKR1C3AKR1C2MGLL | |
| SCHEMBL6426792 | 0.88 | AKR1C3 (0.37) | HSD11B1EPHX2AKR1C3AKR1C2MGLL | |
| SCHEMBL6424892 | 0.88 | LMNA (0.34) | HSD11B1EPHX2AKR1C3AKR1C2MGLL | |
| SCHEMBL6426815 | 0.88 | PDE4B (0.43) | PPARGPPARAMAPK7AKR1C3AKR1C2 | |
| SCHEMBL6424215 | 0.88 | PPARG (0.43) | PPARGHRH3PPARAAKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1643961-A4 | COX-2 AND FAAH INHIBITORS | MICROBIA INC (US) | 2007-09-12 | — | — | EP | disclosed |
| EP-1643961-A2 | COX-2 AND FAAH INHIBITORS | Microbia, Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20050234244-A1 | Synthesis of COX-2 and FAAH inhibitors | IRONWOOD PHARMACEUTICALS, INC. | 2005-10-20 | — | — | US | disclosed |
| WO-2005002525-A2 | COX-2 AND FAAH INHIBITORS | MICROBIA, INC. (US) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234244-A1 | Synthesis of COX-2 and FAAH inhibitors | FAAH2, FAAH, PTGES2 | PPARG 1908/4885HRH3 536/4885PPARA 2460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.